Yeni Bir Miyokin: İrisin

Boström P, Wu J, Jedrychowski MP et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 11; 481(7382):463-468. doi: 10.1038/nature10777.

Castillo-Quan JI. From white to brown fat through the PGC-1α-dependent myokine irisin: implications for diabetes and obesity. Dis Model Mech. 2012; 5(3):293-295. doi: 10.1242/dmm.009894.

Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012; 61(12):1725-1738. doi:10.1016/j.metabol.2012.09.002

Hofmann T, Elbelt U, Ahnis A et al. Irisin Levels are Not Affected by Physical Activity in Patients with Anorexia Nervosa.[b1] Front Endocrinol (Lausanne). 2014; 4:202. doi:10.3389/fendo.2013.00202

Korta P, Pocheć E, Mazur-Biały A. Irisin as a multifunctional protein: Implications for health and certain diseases. Medicina. 2019; 55:485. doi: 10.3390/medicina55080485.

Norheim F, Langleite T.M, Hjorth M et al. The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans. The FEBS J. 2014; 281:739–749. doi: 10.1111/febs.12619.

Schumacher MA, Chinnam N, Ohashi T et al. The structure of irisin reveals a novel intersubunit β-sheet fibronectin type III (FNIII) dimer: Implications for receptor activation. J Biol Chem. 2013; 288:33738–33744. doi: 10.1074/jbc.M113.516641.

Waseem R, Shamsi A, Mohammad T et al. Multispectroscopic and Molecular Docking Insight into Elucidating the Interaction of Irisin with Rivastigmine Tartrate: A Combinational Therapy Approach to Fight Alzheimer’s Disease. ACS Omega. 2021; 6:7910–7921. doi: 10.1021/acsomega.1c00517.

Tiano JP, Springer DA, Rane SG. SMAD3 negatively regulates serum irisin and skeletal muscle FNDC5 and peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) during exercise. J Biol Chem. 2015; 290(12):7671-7684. doi:10.1074/jbc.M114.617399

Panati K, Suneetha Y, Narala VR. Irisin/FNDC5--An updated review. Eur Rev Med Pharmacol Sci. 2016; 20(4):689-697.

Xiong XQ, Chen D, Sun HJ et al. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochim Biophys Acta 2015 Sep; 1852(9):1867-1875. doi: 10.1016/j.bbadis.2015.06.017.

Polyzos SA, Anastasilakis AD, Efstathiadou ZA et al. Irisin in metabolic diseases. Endocrine. 2018 Feb; 59(2):260-274. doi: 10.1007/s12020-017-1476-1.

Rabiee F, Lachinani L, Ghaedi S et al. New insights into the cellular activities of Fndc5/İrisin and its signaling pathways. Cell Biosci. 2020; 10:1–10. doi: 10.1186/s13578-020-00413-3.

Kim H, Wrann C.D, Jedrychowski M et al. İrisin mediates effects on bone and fat via αV integrin receptors. Cell. 2018; 175:1756–1768. doi: 10.1016/j.cell.2018.10.025.

Waseem R, Shamsi A, Mohammad T et al. FNDC5/Irisin: Physiology and Pathophysiology. Molecules. 2022 Feb 8; 27(3):1118. doi: 10.3390/molecules27031118.

Perakakis N, Triantafyllou GA, Fernández-Real JM et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017; 13(6):324-337. doi:10.1038/nrendo.2016.221

Park KH, Zaichenko L, Brinkoetter M et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013; 98:4899–4907. doi: 10.1210/jc.2013-2373.

Liu S, Du F, Li X et al. Effects and underlying mechanisms of irisin on the proliferation and apoptosis of pancreatic β cells. PLoS ONE. 2017; 12:e0175498. doi: 10.1371/journal.pone.0175498.

Chen N, Li Q, Liu J et al. Irisin, an exercise-induced myokine as a metabolic regulator: An updated narrative review. Diabetes Metab Res Rev. 2016; 32:51–59. doi: 10.1002/dmrr.2660.

Choi YK, Kim MK, Bae KH et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract. 2013; 100:96–101. doi: 10.1016/j.diabres.2013.01.007.

Liu JJ, Wong MD, Toy W.C et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013; 27:365–369. doi: 10.1016/j.jdiacomp.2013.03.002.

Zhu D, Wang H, Zhang J et al. Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses. J Mol Cell Cardiol. 2015; 87:138–147. doi: 10.1016/j.yjmcc.2015.07.015.

Colaianni G, Cuscito C, Mongelli T et al. Irisin enhances osteoblast differentiation in vitro. Int J Endocrinol. 2014:1–8. doi: 10.1155/2014/902186.

Qiao X, Nie Y, Ma Y et al. Irisin promotes osteoblast proliferation and differentiation via activating the MAP kinase signaling pathways. Sci Rep. 2016;6:1–12. doi: 10.1038/srep18732.

Singhal V, Lawson EA, Ackerman KE et al. Irisin levels are lower in young amenorrheic athletes compared with eumenorrheic athletes and non-athletes and are associated with bone density and strength estimates. PLoS ONE. 2014; 9:e100218. doi: 10.1371/journal.pone.0100218.

Zhu X, Li X, Wang X et al. Irisin deficiency disturbs bone metabolism. J Cell Physiol. 2021; 236:664–676. doi: 10.1002/jcp.29894.

Piya MK, Harte AL, Sivakumar K et al. The identification of irisin in human cerebrospinal fluid: Influence of adiposity, metabolic markers, and gestational diabetes. Am J Physiol Endocrinol Metab. 2014; 306:E512–E518. doi: 10.1152/ajpendo.00308.2013.

Novelle MG, Contreras C, Romero-Picó A et al. Irisin, two years later. Int J Endocrinol. 2013:1–8. doi: 10.1155/2013/746281.

Wrann CD, White JP., Salogiannnis J et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013; 18:649–659. doi: 10.1016/j.cmet.2013.09.008.

Pesce M, Ballerini P, Paolucci T et al. Irisin and autophagy: First update. Int J Mol Sci. 2020; 21:7587. doi: 10.3390/ijms21207587.

Guo P, Jin Z, Wu H et al. Effects of irisin on the dysfunction of blood–brain barrier in rats after focal cerebral ischemia/reperfusion. Brain Behav. 2019; 9:e01425. doi: 10.1002/brb3.1425.

Yu Q, Li G, Ding Q et al. Irisin protects brain against ischemia/reperfusion injury through suppressing TLR4/MyD88 pathway. Cerebrovasc Dis. 2020; 49:346–354. doi: 10.1159/000505961

Li DJ, Li YH, Yuan HB et al. The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia. Metabolism. 2017; 68:31–42. doi: 10.1016/j.metabol.2016.12.003.

Lourenco MV, Frozza RL, de Freitas GB et al. Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models. Nat Med. 2019; 25:165. doi: 10.1038/s41591-018-0275

Gannon NP, Vaughan RA, Garcia-Smith R et al. Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro. Int J Cancer. 2015; 136:E197–E202. doi: 10.1002/ijc.29142.

Liu J, Song N, Huang Y et al. Irisin inhibits pancreatic cancer cell growth via the AMPK-mTOR pathway. Sci Rep. 2018; 8:1–10. doi: 10.1038/s41598-018-33229-w.

Shao L, Li H, Chen J et al. Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition. Biochem Biophys Res Commun. 2017; 485:598–605. doi: 10.1016/j.bbrc.2016.12.084.

Boström P, Wu J, Jedrychowski MP et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 11; 481(7382):463-468. doi: 10.1038/nature10777.

Castillo-Quan JI. From white to brown fat through the PGC-1α-dependent myokine irisin: implications for diabetes and obesity. Dis Model Mech. 2012; 5(3):293-295. doi: 10.1242/dmm.009894.

Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012; 61(12):1725-1738. doi:10.1016/j.metabol.2012.09.002

Hofmann T, Elbelt U, Ahnis A et al. Irisin Levels are Not Affected by Physical Activity in Patients with Anorexia Nervosa.[b1] Front Endocrinol (Lausanne). 2014; 4:202. doi:10.3389/fendo.2013.00202

Korta P, Pocheć E, Mazur-Biały A. Irisin as a multifunctional protein: Implications for health and certain diseases. Medicina. 2019; 55:485. doi: 10.3390/medicina55080485.

Norheim F, Langleite T.M, Hjorth M et al. The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans. The FEBS J. 2014; 281:739–749. doi: 10.1111/febs.12619.

Schumacher MA, Chinnam N, Ohashi T et al. The structure of irisin reveals a novel intersubunit β-sheet fibronectin type III (FNIII) dimer: Implications for receptor activation. J Biol Chem. 2013; 288:33738–33744. doi: 10.1074/jbc.M113.516641.

Waseem R, Shamsi A, Mohammad T et al. Multispectroscopic and Molecular Docking Insight into Elucidating the Interaction of Irisin with Rivastigmine Tartrate: A Combinational Therapy Approach to Fight Alzheimer’s Disease. ACS Omega. 2021; 6:7910–7921. doi: 10.1021/acsomega.1c00517.

Tiano JP, Springer DA, Rane SG. SMAD3 negatively regulates serum irisin and skeletal muscle FNDC5 and peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) during exercise. J Biol Chem. 2015; 290(12):7671-7684. doi:10.1074/jbc.M114.617399

Panati K, Suneetha Y, Narala VR. Irisin/FNDC5--An updated review. Eur Rev Med Pharmacol Sci. 2016; 20(4):689-697.

Xiong XQ, Chen D, Sun HJ et al. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochim Biophys Acta 2015 Sep; 1852(9):1867-1875. doi: 10.1016/j.bbadis.2015.06.017.

Polyzos SA, Anastasilakis AD, Efstathiadou ZA et al. Irisin in metabolic diseases. Endocrine. 2018 Feb; 59(2):260-274. doi: 10.1007/s12020-017-1476-1.

Rabiee F, Lachinani L, Ghaedi S et al. New insights into the cellular activities of Fndc5/İrisin and its signaling pathways. Cell Biosci. 2020; 10:1–10. doi: 10.1186/s13578-020-00413-3.

Kim H, Wrann C.D, Jedrychowski M et al. İrisin mediates effects on bone and fat via αV integrin receptors. Cell. 2018; 175:1756–1768. doi: 10.1016/j.cell.2018.10.025.

Waseem R, Shamsi A, Mohammad T et al. FNDC5/Irisin: Physiology and Pathophysiology. Molecules. 2022 Feb 8; 27(3):1118. doi: 10.3390/molecules27031118.

Perakakis N, Triantafyllou GA, Fernández-Real JM et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017; 13(6):324-337. doi:10.1038/nrendo.2016.221

Park KH, Zaichenko L, Brinkoetter M et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013; 98:4899–4907. doi: 10.1210/jc.2013-2373.

Liu S, Du F, Li X et al. Effects and underlying mechanisms of irisin on the proliferation and apoptosis of pancreatic β cells. PLoS ONE. 2017; 12:e0175498. doi: 10.1371/journal.pone.0175498.

Chen N, Li Q, Liu J et al. Irisin, an exercise-induced myokine as a metabolic regulator: An updated narrative review. Diabetes Metab Res Rev. 2016; 32:51–59. doi: 10.1002/dmrr.2660.

Choi YK, Kim MK, Bae KH et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract. 2013; 100:96–101. doi: 10.1016/j.diabres.2013.01.007.

Liu JJ, Wong MD, Toy W.C et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013; 27:365–369. doi: 10.1016/j.jdiacomp.2013.03.002.

Zhu D, Wang H, Zhang J et al. Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses. J Mol Cell Cardiol. 2015; 87:138–147. doi: 10.1016/j.yjmcc.2015.07.015.

Colaianni G, Cuscito C, Mongelli T et al. Irisin enhances osteoblast differentiation in vitro. Int J Endocrinol. 2014:1–8. doi: 10.1155/2014/902186.

Qiao X, Nie Y, Ma Y et al. Irisin promotes osteoblast proliferation and differentiation via activating the MAP kinase signaling pathways. Sci Rep. 2016;6:1–12. doi: 10.1038/srep18732.

Singhal V, Lawson EA, Ackerman KE et al. Irisin levels are lower in young amenorrheic athletes compared with eumenorrheic athletes and non-athletes and are associated with bone density and strength estimates. PLoS ONE. 2014; 9:e100218. doi: 10.1371/journal.pone.0100218.

Zhu X, Li X, Wang X et al. Irisin deficiency disturbs bone metabolism. J Cell Physiol. 2021; 236:664–676. doi: 10.1002/jcp.29894.

Piya MK, Harte AL, Sivakumar K et al. The identification of irisin in human cerebrospinal fluid: Influence of adiposity, metabolic markers, and gestational diabetes. Am J Physiol Endocrinol Metab. 2014; 306:E512–E518. doi: 10.1152/ajpendo.00308.2013.

Novelle MG, Contreras C, Romero-Picó A et al. Irisin, two years later. Int J Endocrinol. 2013:1–8. doi: 10.1155/2013/746281.

Wrann CD, White JP., Salogiannnis J et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013; 18:649–659. doi: 10.1016/j.cmet.2013.09.008.

Pesce M, Ballerini P, Paolucci T et al. Irisin and autophagy: First update. Int J Mol Sci. 2020; 21:7587. doi: 10.3390/ijms21207587.

Guo P, Jin Z, Wu H et al. Effects of irisin on the dysfunction of blood–brain barrier in rats after focal cerebral ischemia/reperfusion. Brain Behav. 2019; 9:e01425. doi: 10.1002/brb3.1425.

Yu Q, Li G, Ding Q et al. Irisin protects brain against ischemia/reperfusion injury through suppressing TLR4/MyD88 pathway. Cerebrovasc Dis. 2020; 49:346–354. doi: 10.1159/000505961

Li DJ, Li YH, Yuan HB et al. The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia. Metabolism. 2017; 68:31–42. doi: 10.1016/j.metabol.2016.12.003.

Lourenco MV, Frozza RL, de Freitas GB et al. Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models. Nat Med. 2019; 25:165. doi: 10.1038/s41591-018-0275

Gannon NP, Vaughan RA, Garcia-Smith R et al. Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro. Int J Cancer. 2015; 136:E197–E202. doi: 10.1002/ijc.29142.

Liu J, Song N, Huang Y et al. Irisin inhibits pancreatic cancer cell growth via the AMPK-mTOR pathway. Sci Rep. 2018; 8:1–10. doi: 10.1038/s41598-018-33229-w.

Shao L, Li H, Chen J et al. Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition. Biochem Biophys Res Commun. 2017; 485:598–605. doi: 10.1016/j.bbrc.2016.12.084.